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Abstract
Background
Biologics are used for the treatment of inflammatory bowel diseases, Crohn´s disease and
ulcerative colitis refractory to conventional treatment. In order to allocate healthcare spend-
ing efficiently, costly biologics for inflammatory bowel diseases are an important target for
cost-effectiveness analyses. The aim of this study was to systemically review all published
literature on the cost-effectiveness of biologics for inflammatory bowel diseases and to eval-
uate the methodological quality of cost-effectiveness analyses.
Methods
A literature search was performed using Medline (Ovid), Cochrane Library, and SCOPUS.
All cost-utility analyses comparing biologics with conventional medical treatment, another
biologic treatment, placebo, or surgery for the treatment of inflammatory bowel diseases in
adults were included in this review. All costs were converted to the 2014 euro. The method-
ological quality of the included studies was assessed by Drummond’s, Philips’, and the Con-
solidated Health Economic Evaluation Reporting Standards checklist.
Results
Altogether, 25 studies were included in the review. Among the patients refractory to conven-
tional medical treatment, the incremental cost-effectiveness ratio ranged from dominance to
549,335 €/Quality-Adjusted Life Year compared to the incremental cost-effectiveness ratio
associated with conventional medical treatment. When comparing biologics with another
biologic treatment, the incremental cost-effectiveness ratio ranged from dominance to
24,012,483 €/Quality-Adjusted Life Year. A study including both direct and indirect costs
produced more favorable incremental cost-effectiveness ratios than those produced by
studies including only direct costs.
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Conclusions
With a threshold of 35,000 €/Quality-Adjusted Life Year, biologics seem to be cost-effective
for the induction treatment of active and severe inflammatory bowel disease. Between bio-
logics, the cost-effectiveness remains unclear.
Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are the principal types of inflammatory bowel
diseases (IBDs) [1,2]. IBDs, which are chronic diseases, are characterized by inflammation of
the mucosal lining of the gastrointestinal tract. Their worldwide incidence has increased during
the last decade, but the annual incidence and prevalence of CD and UC are the highest in
Northern Europe and in North America [3]. The incidence of CD is 12.7 per 100,000 person-
years in Europe and 20.2 person-years in North America, while the incidence of UC is 24.3 in
Europe and 19.2 in North America. Unemployment, sick leave, and permanent work disability
are more commonly associated with patients with IBD than with the general population [4].
IBDs affect mainly young adults, causing an even greater economic burden.
Treatment of IBDs is aimed at relieving the symptoms and complications of IBDs as well as
preventing recurrence and improving the patient’s quality of life [5,6]. IBD patients usually
require lifelong medical treatment. Both CD and UC are treated with conventional medical
treatment comprising corticosteroids, aminosalicylates, and immunomodulators (e.g., azathio-
prine, 6-mercaptopurine, and methotrexate). Other treatment options include surgery and diet
therapy [5–7]. Biologic drugs based on two different mechanisms of action are currently avail-
able for the treatment of IBDs [8]. Infliximab (IFX), adalimumab (ADA), golimumab, and cer-
tolizumab pegol (CTZ) are tumor necrosis factor (TNF) inhibitors while natalizumab (NTZ)
and vedolizumab target the α4-integrin [9,10]. Biologics are used to treat IBD refractory to cor-
ticosteroids or immunomodulators or IBD patients who are steroid-dependent or steroid-
intolerant [5,6]. However, biologics are significantly more expensive than conventional drugs
[11,12]. The introduction of TNF inhibitors has changed the cost profile of healthcare costs of
IBDs [12,13]. Nowadays the main source of costs is drugs, especially TNF inhibitors, while ear-
lier the healthcare costs were mainly driven by the hospitalization and the surgery. Biologics
have been shown to be effective in inducing and maintaining remission of IBD [5,6,8,14–16].
Despite their proven efficacy, treatment failures may manifest as primary non-response, sec-
ondary loss of response, or failure of re-induction therapy [5,6,17]. Patients who fail to respond
to TNF inhibitor may benefit from biologic drug with a different mechanism of action, while
an alternative TNF inhibitor may be an effective treatment strategy in case of loss of response
over time. The evidence on the cost-effectiveness of biologics for the treatment of IBD is lim-
ited, and the results of previous systematic reviews are inconsistent and incomplete [18–22].
The field of cost-effectiveness analysis (CEA) involves the comparison of health interven-
tions based on both costs and effectiveness [23,24]. Cost-utility analysis (CUA) is a type of
CEA. The outcome measure of the CUA is the incremental cost-effectiveness ratio (ICER), rep-
resenting the difference in costs between two alternatives divided by the difference in effective-
ness between the same two alternatives. An intervention dominates another if its effectiveness
is higher and its costs are lower [24]. While the health effects are measured in natural units in
the CEA, the measure of consequences in the CUA is the Quality-Adjusted Life Year (QALY)
[24,25]. The QALY takes into account both the quantity and quality of life and can be mea-
sured by either direct or indirect methods. Costs are classified as direct and indirect costs
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[24,26]. Direct costs denote the resources consumed, while indirect costs are costs due to the
loss of productivity related to illness or death. CEA can be conducted using an empirical, obser-
vational, or modeling approach [24]. The modeling study appears to be the most common type
of CEA, combining clinical data and cost data from many sources. Modeling studies can be
tested by sensitivity analysis.
The CEAs provide valuable information for health care decision-makers and enable efficient
spending [24]. The aim of this systematic review is to evaluate existing relevant evidence
regarding the cost-effectiveness of biologics for the treatment of IBDs. The cost-effectiveness of
biologics is compared with placebo treatment, conventional medical treatment, surgery, and
another biologic treatment for adults with diagnosed IBD. The aim of this review is also to ana-
lyze the source of effectiveness of CEAs. Furthermore, this review assesses the quality of the
included CEAs using three different quality assessment checklists.
Materials and Methods
Literature Search
A comprehensive literature search on the cost-effectiveness of biologics for the treatment of
IBDs was performed using Medline (Ovid), Cochrane Library (Cochrane Database of System-
atic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central Register of Con-
trolled Trials, Cochrane Methodology Register, Heath Technology Assessment Database, and
NHS Economic Evaluation Database), and SCOPUS (including Embase) in June 2014. The
search strategies were developed together with an information specialist. The reference lists of
relevant articles were scrutinized. Furthermore, the grey literature and other relevant websites
and databases (Centre for Reviews and Dissemination, Current Controlled Trials, Clinical Tri-
als.gov, and PROSPERO) were hand-searched for relevant studies.
The electronic search strategy was based on patients (IBD, CD, or UC), intervention (bio-
logics), and outcomes (ICER) in different spellings (S1 File). The biologics granted a marketing
authorization by the European Medicines Agency (EMA) or US Food and Drug Administra-
tion (FDA) before May 2014 were included in the literature search strategy [9,10]. No restric-
tion was set based on the year of the publication.
Study Selection
The study selection was based on the inclusion and the exclusion criteria formulated by the
framework of PICOTS i.e., population, intervention, comparator, outcome, timing, and setting
(S1 Table) [27]. The study selection procedure encompassed three main stages. At the first
stage, hits from the electronic databases were imported into reference management software
(RefWorks). After removing duplicate citations, the second stage focused on the evaluation of
the remaining studies based on their titles and abstracts. Studies clearly indicated as irrelevant
to the study subject were excluded. The full articles retrieved that met the inclusion criteria are
included in the current review. The identified abstracts and full texts were screened for eligibil-
ity by one reviewer (SH) and the second reviewer (MB) was consulted.
Data Extraction
Our data extraction form was based on the Cochrane Handbook for Systematic Reviews of
Intervention and the abstract form of the NHS Economic Evaluation Database [28,29]. The fol-
lowing items were extracted: patients, interventions, controls, study design (the type of eco-
nomic evaluation and modeling, perspective, time horizon, country, included costs, the
methods of measuring and valuing outcomes and benefits, discount rate, currency, price year,
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and the type of sensitivity analysis) and outcomes (total costs and benefits, ICER, and the
results of sensitivity analysis). In order to facilitate the comparison of estimates collected from
different studies, all costs were converted to 2014 euro using the exchange rates of the Euro-
pean Central Bank and the value of money index published by Statistics Finland [30,31]. Data
were extracted using Microsoft Excel and performed by one assessor (SH) and ambiguities
were solved by another assessor (MB) for accuracy.
Quality Assessment
The methodological quality of the studies was assessed using three standardized checklists. All
studies were assessed using Drummond’s checklist, published by the British Medical Journal
Working Party, and the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) guidelines [32,33]. In addition, economic evaluations using modeling methods
were assessed using Philips’ checklist [34]. The quality assessment was conducted by one asses-
sor (SH) and ambiguities were resolved by consulting another assessor (MB).
Synthesizing Data
The results of the included CUAs were stratified into 4 subgroups by the type of previous treat-
ments: 1) the cost-effectiveness of biologics in patients without previous treatment, 2) the cost-
effectiveness of biologics in patients with previous conventional medical treatment, 3) the cost-
effectiveness of biologics in patients with previous surgery, and 4) the cost-effectiveness of bio-
logics in patients with previous biologic treatment. Biologic treatments were stratified under
three dosing regimens: a single dose, an episodic treatment, or a maintenance treatment.
ICERs were presented as principal outcomes. In this study, we analyzed the cost-effectiveness
of biologics using the willingness-to-pay threshold of 35,000 €/QALY. A quantitative synthesis
of the study results was not possible because of the heterogeneity in participants, interventions
and study designs.
Results
Literature Search
The database search identified 1828 references, of which 461 were removed as duplicates, leav-
ing 50 studies to be screened by abstracts and titles for further evaluation. After the assessment
of the full text, 31 studies were excluded (S2 File) and 19 studies were included in the review.
Additionally, six full-text articles were included, of which two were found from the bibliogra-
phies of already included studies [35,36] and four from the structured abstracts identified by
the literature search [19,22,37,38]. The hand search revealed no further publications. Alto-
gether, 25 studies were included in the review [19,21,22,35–56]. Study selection is presented in
a flow diagram in Fig 1.
Characteristics of Studies Included in the Review
All CUAs involved economic evaluation modeling, of which 17 and 7 were focused on CD and
UC, respectively, while one study featured both diagnoses. IFX, ADA, NTZ, and CTZ were
studied in 22, 8, two, and one CUAs, respectively. All studies were conducted in North America
or in Europe. One study considered both direct and indirect costs [49]. Three studies were
modelled for lifetime [43,44,46], while most studies used one year time horizon. The study
designs, the interventions, and the comparators of the CUAs were heterogeneous. Table 1 pres-
ents the characteristics of the studies.
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Cost-Effectiveness of Biologics in Patients with No Previous Treatment
In two studies, the cost-effectiveness of biologics was evaluated in CD patients with no previous
treatment (Table 2) [41,50]. In comparison with conventional drugs for the treatment of fistu-
lizing CD, ICERs ascended in excess of 400,000 €/QALY [41] while for newly diagnosed lumi-
nal CD IFX was dominant [50]. No CEAs of biologics in UC patients without earlier treatment
were found (Table 3).
Fig 1. Flow chart of study selection.
doi:10.1371/journal.pone.0145087.g001
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Table 1. Characteristics of the studies.
Author, Year of
publication,
Country
Patients Biologic
treatment
Comparative
treatment
Perspective Time
horizon,
Type of
modelling
Source of
effectiveness
Source of utility
data, Instruments
or valuation
methods for utility
measures
Discount
rate
Crohn’s disease
Ananthakrishnan
et al. 2011, USA
[39]
CD patients,
who were in
surgical
remission after
their ﬁrst
ileocecal
resection
Upfront IFX or
Tailored IFX
Antibiotic Third-party
payer
1 year,
Decision
tree model
Meta-analysis
systematic
review, cohort
studies
Utility values derived
from study by
Casellas et al [57],
for surgery and after
surgery by a panel
of UK
gastroenterologists,
EQ-5D, utilities
valued using UK
tariffs
-
Ananthakrishnan
et al. 2012, USA
[40]
Moderate-to
severe luminal
CD, loss of
response to two
prior TNF
inhibitors
NTZ CTZ Third-party
payer
1 year,
Decision
tree model
RCTs, multi-
center report,
cohort study
Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
-
Arseneau et al.
2001, USA [41]
Fistulizing CD First-line IFX,
second-line
6MP+MET or
IFX episodic
reinfusion or
First-line 6MP
+MET, second-
line IFX
episodic
reinfusion
6MP+MET Third-party
payer
1 year,
Markov
model
Systematic
review
Preference weights
were directly elicited
from CD patients
and healthy
individuals, SG
3% for
costs and
beneﬁts
Assasi et al.
2009, Canada
[22]
Moderate-to
severe CD
(CDAI  200),
refractory to
conventional
medical
treatment
IFX 5 mg/kg
induction and
maintenance
treatment or
ADA induction
treatment (160
mg at week 0,
80 mg at week
2) and
maintenance
treatment (40
mg)
Conventional
medical
treatment or
ADA induction
treatment (160
mg at week 0,
80 mg at week
2) and
maintenance
treatment (40
mg)
Third-party
payer
5 years,
Markov
model
Systematic
review
Utility values derived
from study by
Gregor et al [58], SG
5% for
costs and
QALYs
Blackhouse et al.
2012, Canada
[42]
Refractory to
conventional
medical
treatment
(CDAI > 200)
IFX 5 mg/kg
induction and
maintenance
treatment or
ADA induction
treatment (160
mg at week 0,
80 mg at week
2) and
maintenance
treatment (40
mg)
Conventional
medical
treatment or
ADA induction
treatment (160
mg at week 0,
80 mg at week
2) and
maintenance
treatment (40
mg)
Third-party
payer
5 years,
Markov
model
Systematic
review
Utility values derived
from study by
Gregor et al [58], SG
5% for
costs and
QALYs
(Continued)
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Table 1. (Continued)
Author, Year of
publication,
Country
Patients Biologic
treatment
Comparative
treatment
Perspective Time
horizon,
Type of
modelling
Source of
effectiveness
Source of utility
data, Instruments
or valuation
methods for utility
measures
Discount
rate
Bodger et al.
2009, UK [43]
Moderate-to
severe active
CD,
(CDAI > 220)
IFX 5 mg/kg
+ conventional
medical
treatment or
ADA 80 mg at
week 0, 40 mg
at week 2, 40
mg for
maintenance
+ conventional
treatment
Conventional
treatment
Payer, UK
NHS
60 years
(lifetime),
duration of
treatment
1 or 2
years,
Markov
model
Systematic
review
EQ-5D converted
from CDAI (EQ-
5D = 0.9168–
0.0012 × CDAI,
algorithm by Buxton
et al [59])
3.5% for
costs and
QALYs
Clark et al. 2003,
UK [44]
a, b) Severe
active CD, c)
Fistulizing CD
IFX 5 mg/kg
single dose or
IFX 5 mg/kg
episodic re-
treatment if lost
response or
IFX 5 mg/kg
maintenance
treatment
Placebo Unclear a)
Lifetime,
b)
Unclear,
probably 1
year, c) 1
year, a)
Markov
model, b,
c) Type of
modeling
unclear
a, b) RCTs, c)
RCT
a, b) Utility values
derived from study
by Gregor et al [58],
SG, utility scores
corresponding to the
exact CDAI states,
c) Combination of
CDAI and PDAI
score into utility
using an
unpublished
formulae
6% for
costs and
1.5% for
QALYs
Doherty et al.
2012, USA [45]
CD patients
undergone
intestinal
resection
IFX 5 mg/kg
induction and
maintenance
treatment
AZA / 6MP Societal 1 year, 5
years,
Decision
analysis
model
Meta-analysis Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
3%
Dretzke et al.
2011, UK [21]
Moderate-to-
severe CD,
refractory to
conventional
medical
treatment
IFX induction
treatment or
IFX
maintenance
treatment or
ADA induction
treatment or
ADA
maintenance
treatment
Conventional
medical
treatment or
IFX induction
treatment or
ADA induction
treatment
Payer, UK
NHS
1 year,
Markov
model
Systematic
review
Utility values derived
from study by
Gregor et al [58],
assumptions for
surgery, TTO, EQ-
5D
3.5% for
costs and
QALYs
Jaisson-Hot et al.
2004, France
[46]
Moderate-to-
severe active
ileocolonic non
ﬁstulizing CD
(CDAI 220–
440), resistant
to conventional
medical
treatment
IFX with
retreatment
when patients
relapse/do not
respond or IFX
maintenance
treatment
Surgery
involving
conventional
medical
treatment
Third-party
payer
Lifetime,
Markov
model
RCT, expert
opinion,
cohort study
Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
5% for
costs and
QALYs
Kaplan et al.
2007, USA [47]
CD patients, no
response to 5
mg/kg of IFX
IFX dose
escalation to 10
mg/kg
ADA initiation Unclear 1 year,
Decision
analysis
model
RCTs, cohort
study
Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
-
(Continued)
Systematic Review of Cost-Effectiveness of Biologics for IBDs
PLOSONE | DOI:10.1371/journal.pone.0145087 December 16, 2015 7 / 23
Table 1. (Continued)
Author, Year of
publication,
Country
Patients Biologic
treatment
Comparative
treatment
Perspective Time
horizon,
Type of
modelling
Source of
effectiveness
Source of utility
data, Instruments
or valuation
methods for utility
measures
Discount
rate
Lindsay et al.
2008, UK [48]
Active luminal
non-ﬁstulizing
CD (CDAI 220–
400) or Active
ﬁstulizing CD
IFX 5 mg/kg Conventional
medical
treatment
Payer, UK
NHS
5 years,
Markov
model
RCTs, cohort
study
Utility values derived
from study by
Casellas et al [57],
for surgery and after
surgery by a panel
of UK
gastroenterologists,
EQ-5D, utilities
valued using UK
tariffs
3.5% for
costs and
QALYs
Loftus et al.
2009, UK [49]
Moderate-to-
severe CD
ADA Conventional
medical
treatment
Payer, UK
NHS
1 year,
Type of
modeling
unclear
RCTs Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
3.5% for
costs and
QALYs
Marchetti et al.
2013, Italy [50]
Newly
diagnosed
luminal
moderate-to-
severe CD
patients
Top-down
strategy: IFX 5
mg/kg+AZA à
additional IFX 5
mg/kg+AZA à
MPR+AZA
Step-up
strategy: MPR
à MPR+AZA à
IFX+AZA
Third-party
payer
5 years,
Markov
model
RCT, cohort
studies
EQ-5D and SF-6D
converted from
CDAI, SF-
6D = 0.8129–
0.00076 × CDAI,
EQ-5D = 0.9168–
0.0012 × CDAI, by
Buxton et al
3.5% for
costs and
QALYs
Marshall et al.
2002, Canada
[19]
CD patients
resistant to
conventional
medical
treatment
IFX 5 mg/kg
single dose,
relapses
treated with
conventional
treatment or
IFX 5 mg/kg
single dose,
relapses
treated with IFX
5 mg/kg single
dose or IFX 5
mg/kg single
dose with
responding
patients IFX 5
mg/kg
maintenance
treatment,
relapses
treated with
conventional
medical
treatment
Conventional
treatment or
IFX 5 mg/kg
single dose,
relapses
treated with
conventional
treatment or
IFX 5 mg/kg
single dose,
relapses
treated with
IFX 5 mg/kg
single dose
Third-party
payer
1 year,
Markov
model
RCTs, cohort
study
Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
-
Saito et al. 2013,
UK [51]
Biologic-naive
CD patients
refractory to
conventional
medical
treatment
(CDAI 220–
450)
IFX 5 mg/kg
+AZA
IFX 5 mg/kg Payer, UK
NHS
1 year,
Decision
tree model
RCTs,
observational
study
Utility values derived
from study by
Gregor et al [58],
expert opinion data
for non-responding
active disease, SG,
utility scores
classiﬁed by CDAI
-
(Continued)
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Table 1. (Continued)
Author, Year of
publication,
Country
Patients Biologic
treatment
Comparative
treatment
Perspective Time
horizon,
Type of
modelling
Source of
effectiveness
Source of utility
data, Instruments
or valuation
methods for utility
measures
Discount
rate
Tang et al. 2012,
USA [52]
Moderate-to-
severe CD
(CDAI 220–
450), refractory
to conventional
medical
treatment and
naïve to
biologics
ADA or CTZ or
NTZ
IFX Third-party
payer
1 year,
Decision
analytic
model
RCTs Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
-
Yu et al. 2009,
USA [56]
Active
moderate-to-
severe CD,
candidate for
anti-TNF
maintenance
treatment
ADA (40 mg
every other
week)
maintenance
treatment
IFX 5 mg/kg
maintenance
treatment
Third-party
payer
1 year,
Type of
modeling
unclear
RCTs Utility values derived
from study by
Gregor et al [58],
SG, utility scores
classiﬁed by CDAI
-
Ulcerative colitis
Assasi et al.
2009, Canada
[22]
Moderate-to-
severe UC,
refractory to
conventional
medical
treatment
IFX 5 mg/kg
followed by
switching to
ADA 160 mg
when relapse
or IFX 5 mg/kg
followed by IFX
10 mg/kg dose
escalation
when relapse
Conventional
medical
treatment or
IFX 5 mg/kg
followed by
switching to
ADA 160 mg
when relapse
Third-party
payer
5 years,
Markov
model
Systematic
literature
review
TTO, Utility weights
elicited from UC
patients
5% for
costs and
QALYs
Bryan et al.
2008, UK [37]
Acute
exacerbation of
UC that require
hospitalization,
inadequate
response to
conventional
medical
treatment
IFX 5 mg/kg+IV
CST
Placebo or
CYC or
Surgery
Payer, UK
NHS
1 year,
Decision
analytic
model
RCTs EQ-5D, Utility
weights derived from
UC patients
3.5% for
costs and
QALYs
Chaudhary et al.
2013,
Netherlands [36]
Severely active
UC,
hospitalized
with an acute
exacerbation of
UC, refractory
to IV CST
IFX 5 mg/kg IV CYC or
Surgery
Third-party
payer
1 year,
Decision
analytic
model,
beyond
the ﬁrst
year a
Markov
model
RCTs EQ-5D, valued
using UK tariffs,
TTO for post-
surgery
complications, Utility
scores classiﬁed by
SCAI, Utility weights
derived from UC
patients
4% for
costs,
1.5% for
QALYs
Hyde et al. 2007,
UK [38]
Moderate-to-
severe active
UC, an
inadequate
response to
conventional
medical
treatment
IFX 5 mg/kg Conventional
treatment
Payer, UK
NHS
10 years,
Markov
model
RCTs EQ-5D, Utility
weights derived from
UC patients
3.5% for
costs and
QALYs
(Continued)
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Cost-Effectiveness of Biologics in Patients with Previous Conventional
Medical Treatment
The cost-effectiveness of biologics in CD patients with previous conventional medical treat-
ment was investigated in 12 studies (Table 2) [19,21,22,42–44,46,48,49,51,52,56]. For CD,
ICERs for the biologics ranged from dominance to 549,335 €/QALY when compared with
those of conventional medical treatment [19,21,22,42,43,48,49]. ADA as an intervention treat-
ment resulted in more frequently lower ICERs than did IFX in comparison with conventional
medical treatment [21,22,42,43]. IFX in comparison with surgery was not found to be cost-
Table 1. (Continued)
Author, Year of
publication,
Country
Patients Biologic
treatment
Comparative
treatment
Perspective Time
horizon,
Type of
modelling
Source of
effectiveness
Source of utility
data, Instruments
or valuation
methods for utility
measures
Discount
rate
Punekar et al.
2010, UK [35]
Severely active
UC,
hospitalized
with an acute
exacerbation of
UC, refractory
to IV CST
IFX 5 mg/kg
+ IV CST
IV CST or
CYC+IV CST
or Surgery
Payer, UK
NHS
1 year,
Decision
analytic
model,
beyond
the ﬁrst
year a
Markov
model
A network
meta-analysis
EQ-5D, valued
using UK tariffs,
TTO for post-
surgery
complications, Utility
scores classiﬁed by
SCAI, Utility weights
derived from UC
patients
3.5% for
costs and
QALYs
Tsai et al. 2008,
UK [53]
Moderate-to-
severe UC
Scheduled
maintenance
treatment with
IFX 5 mg/kg
Conventional
medical
treatment
Payer, UK
NHS
10 years,
Markov
model
RCTs EQ-5D, valued
using UK tariffs,
TTO for post-
surgery
complications, Utility
scores classiﬁed by
SCAI, Utility weights
derived from UC
patients
3.5% for
costs and
QALYs
Ung et al. 2014,
Canada [54]
Moderate or
moderately
severe UC,
CST-dependent
and refractory
to thiopurine
IFX 5 mg/kg Conventional
medical
treatment
Third-party
payer
10 years,
Markov
model
RCTs, real life
rates
TTO, VAS, Utility
weights derived from
UC patients
5% for
costs and
QALYs
Xie et al. 2009,
Canada [55]
Moderate-to-
severe UC,
refractory to
conventional
medical
treatment
IFX 5 mg/kg
followed by IFX
10 mg/kg dose
escalation
when relapse
or IFX 5 mg/kg
followed by
switching to
ADA 160 mg
when relapse
Conventional
medical
treatment
Third-party
payer
5 years,
Markov
model
Fixed-effect
meta-analysis
TTO, Utility weights
derived from UC
patients
5% for
costs and
QALYs
!, Transition because of the clinical worsening in the earlier state; 6MP, Mercaptopurine; ADA, Adalimumab; AZA, Azathioprine; CD, Crohn’s disease;
CDAI, Crohn’s disease activity index; CST, Corticosteroid; CTZ, Certolizumab pegol; CYC, Cyclosporine; EQ-5D, European Quality of Life Instrument 5 D;
IBDQ-36, Inﬂammatory Bowel Disease Questionnaire 36; IFX, Inﬂiximab; IV, Intravenous; MET, Metronidazole; MPR, Methylprednisolone; NTZ,
Natalizumab; PDAI, Pouchitis Activity Index; QALY, Quality-Adjusted Life Year; RCT, Randomized controlled trial; SCAI, Simple Clinical Colitis Activity
Index; SF-6D, Short Form-6 dimension; SG, Standard gamble; TNF, Tumor necrosis factor; TTO, Time Trade-Off; UC, Ulcerative colitis; UK NHS,
National Health Service (England); VAS, Visual Analog Scale.
doi:10.1371/journal.pone.0145087.t001
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Table 2. Cost-effectiveness of biologics for the treatment of Crohn’s disease (CD).
Study Intervention
(Biologic
treatment)
Comparison
treatment
ICERa €d/QALY
(including only
directb costs)
ICERa €d/QALY
(including both
directb and
indirectc costs)
Results of
deterministic
sensitivity analysis
(€d/QALY)
Source of research funding
Cost-effectiveness of biologics in CD patients with no previous treatment
Arseneau et al.
2001 [41]
First-line IFX 6MP+MET 438,617 - 219,353–dominance
by comparison
treatment
NIDDK
IFX episodic
reinfusion
6MP+MET 445,477 - 127,314–dominance
by comparison
treatment
NIDDK
Second-line IFX
episodic
reinfusion
6MP+MET 465,394 - 155,109–comparison
treatment is cost-
saving
NIDDK
Marchetti et al.
2013 [50]
Top-down: IFX Step-up: IFX Dominance by
intervention
treatment
- Dominance by
intervention
treatment–93,401
None declared
Cost-effectiveness of biologics in CD patients with earlier conventional medical treatment
Assasi et al. 2009
[22]
IFX Conventional
medical
treatment
155,295 - 142,742–254,029 Canadian federal, provincial, and
territorial governments
ADA Conventional
medical
treatment
134,643 - 120,307–474,352 Canadian federal, provincial, and
territorial governments
IFX ADA 314,250 - 154,436–Dominance
by comparison
treatment
Canadian federal, provincial, and
territorial governments
Blackhouse et al.
2012 [42]
IFX Conventional
medical
treatment
164,626 - 74,434–344,212 Not stated, one of authors has
received an honorarium from Abbott
and acted as a consultant for
Centocor Ortho Biotech Services
ADA Conventional
medical
treatment
142,733 - 63,679–297,508 Not stated, one of authors has
received an honorarium from Abbott
and acted as a consultant for
Centocor Ortho Biotech Services
IFX ADA 331,132 - 157,253–Dominance
by comparison
treatment
Not stated, one of authors has
received an honorarium from Abbott
and acted as a consultant for
Centocor Ortho Biotech Services
Bodger et al. 2009
[43]
IFX Conventional
treatment
31,982 (Duration of
treatment 1 year);
35,759 (Duration of
treatment 2 years)
- 31,227–Dominance
by comparison
treatment
The Welsh Ofﬁce for Research and
Development for Health and Social
Care
ADA Conventional
treatment
12,071 (Duration of
treatment 1 year);
17,309 (Duration of
treatment 2 years)
- 12,692–304,912 The Welsh Ofﬁce for Research and
Development for Health and Social
Care
Clark et al. 2003
[44]
IFX single dose Placebo a) 11,725 b)
236,836 (scenario
1) 163,179
(scenario 2) c)
178,503–215,253
- b) 236,836–529,754
(scenario 1);
163,179–373,921
(scenario 2) c)
143,502–215,253
NICE (UK)
IFX episodic re-
treatment if lost
response
Placebo a) 18,200 b)
126,459 (scenario
1); 108,530
(scenario 2)
- a) 34,651–95,901 b)
82,197–126,459
(scenario 1); 70,544–
108,530 (scenario 2)
NICE (UK)
IFX
maintenance
treatment
Placebo a) 147,702 - - NICE (UK)
(Continued)
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Table 2. (Continued)
Study Intervention
(Biologic
treatment)
Comparison
treatment
ICERa €d/QALY
(including only
directb costs)
ICERa €d/QALY
(including both
directb and
indirectc costs)
Results of
deterministic
sensitivity analysis
(€d/QALY)
Source of research funding
Dreztke et al. 2011
[21]
IFX induction
treatment
Conventional
medical
treatment
Dominance by
intervention
treatment (Severe
CD); 162,941
(Moderate CD)
- 17,346–123,198 NICE (UK)
IFX
maintenance
treatment
Conventional
medical
treatment
118,015 (Severe
CD); 549,335
(Moderate CD)
- 63,127–2,764,027 NICE (UK)
ADA induction
treatment
Conventional
medical
treatment
Dominance by
intervention
treatment
- Dominance by
intervention treatment
NICE (UK)
ADA
maintenance
treatment
Conventional
medical
treatment
13,387 (Severe
CD); 276,539
(Moderate CD)
- Dominance by
intervention
treatment–1,180,345
NICE (UK)
IFX
maintenance
treatment
IFX induction
treatment
8,689,409 (Severe
CD); 24,012,483
(Moderate CD)
- 553,635–8,568,483 NICE (UK)
ADA
maintenance
treatment
ADA induction
treatment
8,603,033 (Severe
CD); 24,012,483
(Moderate CD)
- Dominance by
intervention
treatment–8,810,335
NICE (UK)
Jaisson-Hot et al.
2004 [46]
IFX re-treatment Surgery 77,002 - 77,002–dominance by
comparison treatment
Not stated
IFX
maintenance
treatment
Surgery 947,769 - 947,769–dominance
by comparison
treatment
Not stated
Lindsay et al. 2008
[48]
IFX Conventional
medical
treatment
45,137 (Severe
active luminal CD);
51,397 (Fistulizing
CD)
- 41,032–67,111
(Severe active luminal
CD); 46,724–76,367
(Fistulizing CD)
Schering Plough Ltd
Loftus et al. 2009
[49]
ADA Conventional
medical
treatment
27,751 (Severe
CD); 58,271
(Moderate-to-
severe CD)
9,069 (Severe
CD); 42,554
(Moderate-to-
severe CD)
11,315–59,133
(Severe CD); 30,876–
99,455 (Moderate-to-
severe CD)
Abbott Laboratories
Marshall et al.
2002 [19]
IFX single dose Conventional
treatment
162,181 - 34,908–Dominance
by comparison
treatment
CCOHTA (now CADTH)
IFX single dose
with re-
treatment
IFX single dose 429,715 - Dominance by
intervention
treatment–533,605
CCOHTA (now CADTH)
IFX
maintenance
treatment
IFX single dose
with re-
treatment
623,013 - 1,620–736,716 CCOHTA (now CADTH)
Saito et al. 2013
[51]
IFX+AZA IFX 34,549 - 23,776–63,178 CISA
Tang et al. 2012
[52]
ADA IFX - - - Not stated
CTZ IFX - - - Not stated
NTZ IFX - - - Not stated
Yu et al. 2009 [56] ADA
maintenance
treatment
IFX
maintenance
treatment
Dominance by
intervention
treatment
- Dominance by
intervention treatment
Abbott Laboratories
Cost-effectiveness of biologics in CD patients with earlier surgical treatment
Ananthakrishnan
et al. 2011 [39]
Upfront IFX Antibiotic 2,268,986 - 594,301–5,485,175 None declared, one author receives
research support from Procter and
Gamble and Warner Chilcott
(Continued)
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effective, with ICERs in excess of 77,000 €/QALY [46]. Between biologics cost-effectiveness
was investigated in four studies [22,42,52,56]. ICERs above 300,000 €/QALY were seen when
comparing IFX with ADA [22,42], while ADA maintenance treatment appeared to be domi-
nant in comparison with IFX maintenance treatment [56].
Two studies evaluated the cost-effectiveness of biologics for different activity levels of CD
resulting in more favorable ICERs for severe CD than for moderate CD [21,49]. The cost-effec-
tiveness of biologics for fistulizing CD was examined in two studies (ICERs above 51,000
€/QALY) [44,48] and for luminal CD in two studies (ICERs above 45,000 €/QALY) [46,48].
Biologic induction treatment resulted in lower ICERs than maintenance treatment [21]. In one
study, IFX and corticosteroid combination treatment was shown to be cost-effective in com-
parison with IFX monotherapy [51]. One study found more favorable ICER when including
both direct and indirect costs than only direct costs [49]. The ICERs of the studies using life-
time horizon ranged from 11,725 to 947,769 €/QALY [43,44,46].
Eight CUAs evaluated the cost-effectiveness of biologics in UC patients with previous con-
ventional medical treatment (Table 3) [22,35–38,53–55]. ICER remained below 35,000
€/QALY when comparing IFX with either conventional medical treatment, surgery, or placebo
treatment for UC patients with acute exacerbation requiring hospitalization [35–37]. When
investigating the cost-effectiveness of IFX for patients with moderate-to-severe UC, ICER ran-
ged from 33,067 €/QALY to 407,499 €/QALY [22,38,53–55].
Table 2. (Continued)
Study Intervention
(Biologic
treatment)
Comparison
treatment
ICERa €d/QALY
(including only
directb costs)
ICERa €d/QALY
(including both
directb and
indirectc costs)
Results of
deterministic
sensitivity analysis
(€d/QALY)
Source of research funding
Tailored IFX Antibiotic Dominance by
comparison
treatment
Dominancy by
comparison treatment
None declared, one author receives
research support from Procter and
Gamble and Warner Chilcott
Doherty et al. 2012
[45]
IFX AZA/6MP 1,449,979 (Time
horizon 1 year);
1,823,102 (Time
horizon 5 years)
- 1,449,979–
Dominance by
comparison treatment
Pﬁzer Inc. and Merck & Co. One of
authors receives research funding
from Proctor & Gamble, Shire and
Salix
Cost-effectiveness of biologics in CD patients with earlier biological treatment
Ananthakrishnan
et al. 2012 [40]
NTZ CTZ 314,020 - Dominance by
intervention treatment
—Dominance by
comparison treatment
None declared
Kaplan et al. 2007
[47]
IFX dose
escalation
ADA 311,432 - 46,862–Dominance
by comparison
treatment
None declared, authors have
received research grants from
UCB Pharma, Abbott
Laboratories, Centocor, Bristol-
Myers Squibb, Elan
Pharmaceuticals, Prometheus
Laboratories, Otsuka America
Pharmaceuticals Inc
ADA, Adalimumab; CEGIIR, Centre of Excellence for Gastrointestinal Inﬂammation and Immunity Research; CST, Corticosteroid; CYC, Cyclosporine; IFX,
Inﬂiximab; IV, Intravenous; NICE, National Institute for Health and Care Excellence; RCT, Randomized controlled trial; QALY, Quality-Adjusted Life Year;
TTO, Time Trade-off; VAS, Visual analog scale.
aThe difference in costs divided by the difference in health effects.
bThe resources consumed.
cProductivity costs for the patient and family members.
dAll costs converted into 2014 euro.
doi:10.1371/journal.pone.0145087.t002
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Cost-Effectiveness of Biologics in Patients with Previous Surgery
The cost-effectiveness of biologics in CD patients having undergone intestinal resection was
investigated in two CUAs (Table 2) [39,45]. IFX in comparison with conventional medical
treatment was not cost-effective, producing extremely unfavorable ICERs above 1,400,000
€/QALY. No studies investigated the cost-effectiveness of biologics in UC patients with previ-
ous surgery (Table 3).
Cost-Effectiveness of Biologics in Patients with Previous Biologic
Treatment
The cost-effectiveness of biologics in CD patients with prior biologic treatment was investi-
gated in two CUAs (Table 2) [40,47]. Neither IFX dose escalation in comparison with second-
line ADA nor third-line CTZ in comparison with NTZ was cost-effective (ICERs above
300,000 €/QALY). No studies evaluated the cost-effectiveness of biologics in UC patients with
prior TNF inhibitor treatment (Table 3).
Effectiveness Data
In all studies, the source of effectiveness was based on at least one randomized controlled trial
(RCT). One study used real life data published by specialized inflammatory bowel disease clin-
ics and compared those findings with data from RCTs [54].
In 13 studies focused on CD, utility values were obtained by the Standard Gamble (SG) val-
uation technique [19,22,40–42,44–47,49,51,52,56]. In twelve studies, the utilities were derived
from study by Gregor et al [58] which used the SG method in CD patients to define utility
scores and correlated them with the Crohn’s disease Activity Index (CDAI) [19,22,40,42,44–
47,49,51,52,56]. In two studies [39,48], health state preferences were driven from the study by
Casellas et al [57] which estimated health state preferences of Spanish CD patients using the
European Quality of Life Instrument 5 D (EQ-5D) and converted to utilities using UK tariffs.
In two studies [43,50] the estimated EQ-5D utility scores were converted from CDAI scores
based on the algorithm developed by Buxton et al [59].
In three studies concerning UC [35,36,53], the utility scores were obtained from an UC
patient survey carried out in Cardiff Hospital using the EQ-5D and valued using UK tariffs
[60]. Utilities were further classified into health states by a Simple Clinical Colitis Activity
Index (SCAI). Two studies [22,55] used utilities from patients using Time Trade-off (TTO) val-
uation technique [61].
Quality Assessment
The results of the quality assessment are shown in Fig 2. The mean amount of fulfilled criteria
were 24.9 out of 35 (median 26, range 14–30), 29.6 out of 57 (median 29, range 14–46), and
18.2 out of 24 (median 18, range 10–23) for Drummond’s checklist, Philip’s checklist, and the
CHEERS guideline, respectively. Studies by Assasi et al, Bryan et al, and Dretzke et al, which all
are Health Technology Assessment (HTA) reports, fulfilled most criteria of the applicable
items [21,22,37]. The quality elements most commonly omitted from the economic analyses
were information on adjustments for data identification, baseline data, treatment effects, data
incorporation, and assessment of uncertainty (S2 Table).
Discussion
Altogether, 25 studies were included in this systematic review. The number of the included
studies in this review was higher than in previously published reviews for IBD [18–22].
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Table 3. Cost-effectiveness of biologics for the treatment of ulcerative colitis (UC).
Study Intervention
(Biologic
treatment)
Comparison
treatment
ICERa €d/QALY
(including only directb
costs)
ICERa €d/
QALY
(including
both directb
and indirectc
costs)
Results of
deterministic
sensitivity analysis
(€d/QALY)
Source of research
funding, Conﬂict of
interest of authors
Cost-effectiveness of biologics in UC patients with earlier conventional medical treatment
Assasi et al.
2009 [22]
IFX followed by
IFX dose
escalation when
relapse
Conventional
medical
treatment
407,499 - 294,007–629,598 Canadian federal,
provincial, and territorial
governments
IFX followed by
switching to
ADA when
relapse
Conventional
medical
treatment
253,537 - 191,701–373,298 Canadian federal,
provincial, and territorial
governments
IFX followed by
IFX dose
escalation when
relapse
IFX followed by
switching to
ADA when
relapse
Dominance by
comparison treatment
- - Canadian federal,
provincial, and territorial
governments
Bryan et al.
2008 [37]
IFX CYC 33,486 - 2,399–108,262 NICE (UK)
IFX Placebo 20,829 7,745–24,268 NICE (UK)
IFX Surgery 24,293 - 2,470–109,612 NICE (UK)
Chaudhary
et al. 2013
[36]
IFX IV CYC 26,479 - 17,609–38,985 Merck & Co
IFX Surgery 15,967 - 11,614–24,475 Merck & Co
Hyde et al.
2007 [38]
IFX Conventional
treatment
72,711 - 29,363–101,989 NICE (UK)
Punekar
et al. 2010
[35]
IFX IV CST 19,198 - Dominance by
intervention treatment–
94,322
Schering-Plough Ltd
IFX CYC+IV CST 30,871 - Dominance by
intervention treatment–
108,272
Schering-Plough Ltd
IFX Surgery 22,161 - Dominance by
intervention treatment–
109,279
Schering-Plough Ltd
Tsai et al.
2008 [53]
IFX
maintenance
treatment
Conventional
medical
treatment
46,041 (responders
only); 33,067 (remission
only)
- 353,367–144,921
(responders only);
24,726–78,511
(remission only)
Schering-Plough Ltd
Ung et al.
2014 [54]
IFX Conventional
medical
treatment
Source of effectiveness
based on RCTs: 115,639
(TTO); 99,663 (VAS),
Source of effectiveness
based on real-life
studies: 66,949 (TTO);
60,101 (VAS)
- Source of effectiveness
based on RCTs:
54,777–248,016,
Source of effectiveness
based on real-life
studies: 31,192–94,337
CEGIIR and the Alberta
Innovates—Health
Solutions supported
Alberta IBD Consortium
Xie et al.
2009 [55]
IFX dose
escalating when
relapse
Conventional
medical
treatment
407,499 - 303,515–629,598 Not stated, Conﬂict of
interest: Eli Lilly Canada
Inc, GlaxoSmithKline Inc,
Abbott Laboratories Ltd,
Janssen-Ortho Inc.,
Hoffman-La Roche Ltd
(Continued)
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However, it is noteworthy that articles by Blackhouse et al and Xie et al are part of the study by
Assasi et al [22,42,55]. A majority of the included studies used IFX or ADA as an intervention
treatment, while NTZ and CTZ were investigated only in few studies, and none of the studies
considered golimumab. Because of the variability in data input and heterogeneous study
designs, the quantitative synthesis of the studies was not possible.
On the basis of the current review and willingness-to-pay threshold of 35,000 €/QALY, bio-
logics in comparison with conventional medical treatment and placebo treatment were found
to be cost-effective for severe CD in remission induction, while for maintenance treatment
cost-effectiveness remained unclear. Biologics were not cost-effective in comparison with sur-
gery for the treatment of severe CD. In moderate CD, biologics did not seem to be cost-effec-
tive. Biologics were found not to be cost-effective among CD patients having undergone
intestinal resection. ADA was shown to be a more cost-effective biologic treatment option than
IFX. Cost-effectiveness between individual biologics remained unclear, however.
Biologics were cost-effective for the treatment of acute exacerbation of severely active UC
when compared with either conventional medical treatment, surgery, or placebo treatment.
For moderate UC, biologics were not cost-effective. The cost-effectiveness between different
biologics remained unclear in UC.
The literature search found five earlier published systematic reviews of the cost-effectiveness
of biologics for IBDs [18–22]. In previous reviews, the conclusions have been contradictory
and partially unreliable due to a low amount of included CUAs. Four out of five previous
reviews evaluated the cost-effectiveness of biologics for CD [18–21], while one assessed the
cost-effectiveness of biologics in both CD and UC [22]. IFX was the only biologic treatment in
four reviews [19–22]. Meanwhile, the latest systematic review by Tang et al included IFX,
ADA, CTZ, and NTZ and came to a conclusion that the biologics are cost-effective for CD in
certain clinical situations which was congruent with this review [18]. The earlier review by
Assasi et al [22] included one CUA [53] showing that scheduled maintenance treatment with
IFX is a cost-effective option for UC [22]. The studies included in our review focused mainly
Table 3. (Continued)
Study Intervention
(Biologic
treatment)
Comparison
treatment
ICERa €d/QALY
(including only directb
costs)
ICERa €d/
QALY
(including
both directb
and indirectc
costs)
Results of
deterministic
sensitivity analysis
(€d/QALY)
Source of research
funding, Conﬂict of
interest of authors
IFX switching to
ADA when
relapse
Conventional
medical
treatment
253,537 - 193,349–373,298 Not stated, Conﬂict of
interest: Eli Lilly Canada
Inc, GlaxoSmithKline Inc,
Abbott Laboratories Ltd,
Janssen-Ortho Inc.,
Hoffman-La Roche Ltd
ADA, Adalimumab; CEGIIR, Centre of Excellence for Gastrointestinal Inﬂammation and Immunity Research; CST, Corticosteroid; CYC, Cyclosporine; IFX,
Inﬂiximab; IV, Intravenous; NICE, National Institute for Health and Care Excellence; RCT, Randomized controlled trial; QALY, Quality-Adjusted Life Year;
TTO, Time Trade-off; VAS, Visual analog scale.
aThe difference in costs divided by the difference in health effects.
bThe resources consumed.
cProductivity costs for the patient and family members.
dAll costs converted into 2014 euro.
doi:10.1371/journal.pone.0145087.t003
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on induction treatment and revealed no further evidence of the cost-effectiveness of biologic
maintenance treatment for UC.
An important issue affecting the conclusions of CEAs relates to the established willingness-
to-pay threshold. In the UK, the National Institute of Health and Clinical Excellence (NICE)
supports treatments with ICER no higher than 30,000 £ (*35,000 €) per QALY [62], which we
used as a threshold in this study. However, there has been much debate as to whether this
threshold is too low, and many health care systems have not set a cost-effectiveness threshold
at all [54]. The willingness-to-pay threshold commonly used by the Canadian Drug Expert
Committee is 80,000 CDN$ (*75,000 €) per QALY [63], while the threshold of 50,000–
100,000 US$ (*38,00–75,000 €) per QALY is often used in the US [64,65]. According to the
World Health Organization, an intervention is cost-effective if the cost of intervention per
QALY is less than three times the country’s annual gross domestic product [66]. Even if those
thresholds had been used in this review, biologics would not have been deemed cost-effective
in most studies. It should be noted that the selection of the willingness-to-pay threshold
Fig 2. Quality assessment of the included studies.
doi:10.1371/journal.pone.0145087.g002
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depends on the relevant context, including the disease burden and the budget of the setting in
question.
Most studies used the perspective of the local public health care service or the insurance sys-
tem while only paying attention to direct costs. Only one study included both direct and indi-
rect costs and reported more favorable ICER when considering both direct and indirect costs
in comparison with only direct costs [49]. No clear guidelines exist on how productivity losses
should be determined causing concern for the validity of the cost estimates. Included cost com-
ponents and their valuing methods can be difficult to identify based on the publications. Fur-
thermore, productivity costs included in CUA may cause a risk of double-counting as the
impact of morbidity is already included in the calculation of QALY [26]. The patient´s earnings
and leisure activities affect variability on the value of the individual´s time [24]. The differences
in overall labor costs, health policy, and other health system factors make challenging to com-
pare results between countries. IBDs as chronic diseases are usually diagnosed in early adult-
hood causing a severe impact on productivity costs. Even though biologics increase the drug
costs, they are assumed to improve the health status and to reduce the burden on resources out-
side the health care system such as absenteeism from work [67]. Consequently, it is appropriate
to include indirect costs in CUA, but indirect costs should be presented separately from direct
costs [24,26].
When evaluating effectiveness, it is scientifically and ethically important to use the most
appropriate alternative treatment as the control group. The comparator with a good efficacy
and safety profile should act as the most cost-effective alternative treatment and is usually the
intervention most used in clinical practice [32,68]. However, recommendations on the appro-
priate comparator vary across countries and depend on the research question [68]. A majority
of the included studies used the “standard care” or “usual care” as the comparator.
Source of effectiveness data has substantial influence on model results. RCT data was used
as effectiveness data in all included CUAs. RCTs give information about efficacy determined in
ideal circumstances and cause a risk of overestimating effectiveness in comparison with the
treatment in routine healthcare. Therefore, it is plausible to assume that the CUAs using
RCTs as a source of effectiveness produce lower ICERs than real-world data. Contrary to that
assumption, only one of the included studies derived information from real life studies and
resulted in more favorable ICERs when using response rates from real life data rather than
from RCTs [54]. However, the uncertainty in economic evaluations, especially in modeling
studies, can arise from numerous methodological disagreements among analyses. Uncertainty
caused by e.g., using multiple data sources and extrapolation beyond the time horizon of the
study involving the use of assumptions was tested by sensitivity analysis in most studies.
In most studies, the source of utility data was reported inadequately and considerable varia-
tion existed in the instruments used to collect it. Direct elicitation methods (e.g., SG, TTO)
were used more frequently than indirect methods (e.g., EQ-5D). With direct methods patients
directly score their preferences for health states and make judgments based on their own rela-
tive values, while indirect methods are based on the patients’ responses to surveys about vari-
ous aspects of health states [25]. The methods of direct elicitation can be complex and time
consuming. In most cases, indirect utility estimates were obtained by determining the relation-
ship between values on a disease-specific measure to a generic quality of life measure. This is
necessary because of the fact that the generic measures have been applied in few studies, while
disease specific measures such as CDAI are commonly used in RCTs. The application of differ-
ent algorithms for conversions creates a further source of heterogeneity in ICER estimates.
Because of the variation in the methods used and in the preferences across individuals, the
QALYs may vary widely between the studies and this affects the results of the CUAs.
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Based on previous literature, studies with longer time horizon produce more favorable
ICERs than studies with shorter time horizons [49,53]. As biologics improve patients´ health
status [67], they have potential to yield gain in terms of reductions in hospitalization, surgeries,
and incapacity in future. However, the correlation between the length of the time horizon and
cost-effectiveness analyses remains unclear in our study. Although the lifetime horizon is
appropriate to capture all health effects and costs for chronic diseases, in most modelling stud-
ies the time horizon was limited to one year by the availability of the relevant data and to avoid
the bias caused by extrapolation to a longer time horizon.
When considering the previously published systematic reviews, only one study used the
standardized quality assessment checklist to evaluate the quality of the included CUAs. As far
as we know, this is the first systematic review assessing the quality of economic evaluations by
three different checklists. Drummond’s checklist is recommended to inform appraisal of the
methodological quality of full economic evaluations [32,69]. Drummond’s checklist is relevant
but not sufficient for modeling studies. Therefore, the modeling’s were also assessed using
Philip’s checklist [32,34,69]. The CHEERS guideline includes additional items relating to the
author’s disclosure of funding sources and conflicts of interest, sufficient information in article
titles, and structured abstracts [33]. The CHEERS guideline evaluates the reporting of the study
while Drummond’s checklist and Philips’ checklist are designed to assess the methodological
quality of economic evaluations.
The amount of the fulfilled items according to Drummond’s checklist and the CHEERS
guideline was higher than using Philips’ checklist. The reasons may be aims of the checklist
and the extensiveness of Philips’ checklist including several topics relevant to modeling studies
and not considered in Drummond’s checklist and the CHEERS guideline. On average, the
same CUAs fulfilled the highest amount of the applicable items according to all three check-
lists. Most of the studies, which fulfilled most criteria of quality assessment checklists, were
HTA reports. Almost half of the included CUAs were funded by the pharmaceutical company
or authors had received funding from the pharmaceutical companies during the research proj-
ect [35,36,42,45,47–49,53,55,56]. Many of the studies funded by the pharmaceutical company
produced favorable ICERs [35,36,48,49,53,56]. However, it remained unclear whether the
source of funding had an effect on the study results. In addition, the relation between the stud-
ies funded by a pharmaceutical company and fulfillment of applicable quality assessment crite-
ria was found to be unclear.
The current review was carefully designed beforehand and documented transparently,
improving the validity of the study. The study selection, the data extraction, and the quality
assessment were performed by one assessor and any ambiguity was resolved with a second
assessor to avoid human mistakes and to improve the reliability of the study. The comprehen-
sive literature search was utilized to minimize bias. The intervention treatments included in the
search strategy were limited to biologics that had been granted a marketing authorization by
the EMA or FDA for the treatment of IBD. Vedolizumab was not included in the search strat-
egy because its marketing authorization was not granted until the planning and realization of
the search strategy was completed.
However, because of a limited amount of available CEAs and some inconsistent results, con-
clusions remain partially uncertain. Furthermore, variability in data input and heterogeneity in
study designs made it challenging to compare studies reliably. To improve the reporting of an
individual CEA, it is appropriate to use quality assessment checklists. When using checklists,
economic evaluations become more consistent, transparent, and informative. The most impor-
tant predictors of good cost-effectiveness of the biologics were disease activity, the duration of
the biological treatment, and the treatment strategy. Further research is needed to confirm
cost-effectiveness in moderate IBD. Future studies should evaluate the cost-effectiveness of all
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available biologic treatments for IBDs. In addition, CEAs between two different biologics are
required to find the most cost-effective treatment strategy for IBD patients.
In conclusion, biologics seem to be cost-effective for the induction treatment of active and
severe IBD, but not for the maintenance treatment. Whether there are differences in the cost-
effectiveness between biologics remains unclear.
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